CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners
Tweet Send to a Friend
Leerink Partners analyst Rick Bienkowski lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $67.00 (from $68.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
